問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇東弘

Recruiting

List

48Cases

2020-12-15 - 2026-01-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-11-30 - 2026-09-30

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
9Sites

Recruiting9Sites

2024-01-12 - 2026-09-11

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  • Condition/Disease

    Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  • Test Drug

    Efruxifermin

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting2Sites

Study ended1Sites

2023-01-05 - 2026-12-31

Phase III

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 2)

  • Condition/Disease

    Chronic Hepatitis B、Hepatitis B, Chronic

  • Test Drug

    GSK3228836/Bepirovirsen

Participate Sites
4Sites

Recruiting4Sites

2023-02-24 - 2025-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2020-05-01 - 2025-03-31

Phase II

A Phase II, Randomised, Adaptive, Open-Label Platform Trial To Evaluate Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    RO7049389、RO7020531、Vemlidy韋立得、Viread 惠立妥、Baraclude 貝樂克

Participate Sites
6Sites

Recruiting6Sites

2022-09-01 - 2026-08-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-12-20 - 2024-08-16

IIT

Phase II

Regorafenib plus tislelizumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC)

  • Condition/Disease

    advanced hepatocellular carcinoma (HCC)

  • Test Drug

    1. Regorafenib (BAY-73-4506) 2. Tislelizumab (BGB-A317)

Participate Sites
2Sites

Recruiting2Sites

2017-02-01 - 2019-06-30

Others

A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects

  • Condition/Disease

    The plan includes adult male and female CHB subjects aged 18 to 70 (inclusive) who are not currently receiving CHB treatment. Part 1 (Groups A, B, C, and D) will include HBeAg-positive subjects, while Part 1 (Group C1) will include HBeAg-negative subjects. After completing part 1 of the administration (after reviewing the safety, tolerability, PK and PD differences between HBeAg status), the specific CHB group included in part 2 will be determined

  • Test Drug

    GSK3389404

Participate Sites
9Sites

Recruiting8Sites

2023-02-15 - 2025-06-30

Phase I

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-2829GS-6779

Participate Sites
10Sites

Recruiting10Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB